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Rates of Potentially Inappropriate Dosing of Direct-Acting Oral
Anticoagulants and Associations With Geriatric Conditions Among
Older Patients With Atrial Fibrillation: The SAGE-AF Study
Saket Sanghai , MBBS; Cecillia Wong, MD; Ziyue Wang, MPH; Pia Clive, PharmD; Wenisa Tran, PharmD; Molly Waring, PhD;
Robert Goldberg, PhD; Robert Hayward, MD; Jane S. Saczynski, PhD; David D. McManus, MD, ScM
Background-—Direct-acting oral anticoagulant (DOAC) dosing guidelines for atrial fibrillation recommend dose alteration based on
age, renal function, body weight, and drug-drug interactions. There is paucity of data describing the frequency and factors
associated with prescription of potentially inappropriate doses.
Methods and Results-—In the ongoing SAGE-AF (Systematic Assessment of Geriatric Elements in Atrial Fibrillation) study, we
performed geriatric assessments (frailty, cognitive impairment, sensory impairments, social isolation, and depression) for
participants with atrial fibrillation (age ≥65 years, CHA2DS2VASc ≥2, no anticoagulant contraindications). We developed an
algorithm to analyze DOAC dose appropriateness accounting for drug-drug interactions, age, renal function, and body weight. We
also examined whether geriatric impairments were related to inappropriate dosing. Of 1064 patients prescribed anticoagulants,
460 received a DOAC. Participants were aged 747 years, 49% were women, and 82% were white. A quarter (23%; n=105) of
participants received inappropriate DOAC dose, of whom 82 (78%) were underdosed and 23 (22%) were overdosed. Among
participants receiving an inappropriate dose, 12 (11%) were identified using the drug-drug interactions criteria and would have
otherwise been misclassified. In multivariable regression analyses, older age, higher CHA2DS2VASc score, and history of renal
failure were associated with inappropriate DOAC dosing (P<0.05). Geriatric conditions were not associated with inappropriate
dosing.
Conclusions-—In this cohort, over 20% of older patients with atrial fibrillation treated with DOACs were prescribed an inappropriate
dose, with most being underdosed. Drug-drug interactions were common. Factors that influence prescription of guideline-
nonadherent doses may be perception of higher bleeding risk or presence of renal failure in addition to lack of familiarity with
dosing guidelines. ( J Am Heart Assoc. 2020;9:e014108. DOI: 10.1161/JAHA.119.014108.)
Key Words: anticoagulant • atrial fibrillation • geriatrics • off-label dosing
D irect-acting oral anticoagulant (DOAC)medications includ-ing dabigatran, apixaban, rivaroxaban, and edoxaban are
approved by the Food and Drug Administration (FDA) for the
prevention of thromboembolic events in patients with nonvalvu-
lar atrial fibrillation (AF). DOACs have a class I recommendation
in the current AF guidelines and are increasingly being used in
clinical practice.1 Data from large randomized clinical trials have
shown each of these individual agents to be noninferior to
warfarin for prevention of systemic thromboembolism with a
similar or better safety profile.2–5 Unlike warfarin, they do not
require intensive laboratory monitoring, making them easier to
prescribe and use. However, their FDA approval was granted at
specific doses with dose adjustments for age, renal function,
body weight, or concomitant drug therapies.6–9
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Recent studies have shown that 10% to 15% patients
receiving DOAC prescriptions were treated with potentially
inappropriate doses.10,11 Inappropriate dosing has potential
clinical consequences, including thromboembolism, bleeding,
and death. However, the reasons for choosing an off-label
dosing regimen in such patients are not clear based on
previous data.11–13 Older patients with AF are especially
susceptible to the adverse effects associated with inappro-
priate drug dosing attributable to decreased drug metabo-
lism, increased prevalence of hepatic and renal dysfunction,
and higher likelihood of drug-drug interactions as a result of
frequent polypharmacy. Previously published studies have
either ignored or incompletely evaluated the prevalence and
effect of drug-drug interactions on DOAC dosing,10–13
limiting their precision. In these studies, older age, female
sex, and higher stroke and bleeding risk scores have been
associated with off-label prescribing.13 However, whether
impairments common in the geriatric population and related
to adverse drug-related outcomes, such as cognition and
frailty, affect DOAC dosing in these patients have not been
examined.
Using data from a prospective cohort of elderly patients
65 years and older with robust phenotyping of geriatric
impairments, we sought to describe the frequency of
inappropriate dosing of DOACs while systematically account-
ing for drug-drug interactions, renal function, and other
factors related to dosing of DOAC medications. Second, we
aimed to examine the clinical characteristics, including
geriatric conditions, that might be associated with inappro-
priate dosing. We hypothesized that frailty would relate to
higher odds of off-label dosing, with frail patients with AF
being more likely to be underdosed.
Methods
The data that support the findings of this study are available
from SAGE-AF (Systematic Assessment of Geriatric Elements
in Atrial Fibrillation) study principal investigators upon
reasonable request (david.mcmanus@umassmemorial.org and
j.saczynski@northeastern.edu).
SAGE-AF Cohort
The SAGE-AF study is an ongoing large, multicenter prospec-
tive cohort study examining the relationship between the
components of a comprehensive geriatric assessment and
outcomes in AF among patients older than 65 years. Details
of the SAGE-AF study have been previously published.14
Briefly, SAGE-AF enrolled patients with ambulatory AF aged
65 years and older with a CHA2DS2VASc score of at least 2
from 5 recruitment sites in Massachusetts and Georgia.
Patients were excluded if they had an absolute contraindica-
tion to oral anticoagulation or if they had an additional
indication for anticoagulation apart from AF, such as
mechanical heart valves or venous thromboembolism. Partic-
ipants who consented to the study underwent standard
history and physical examinations in the context of their
routine care on the same day as the SAGE-AF interview. All
participants provided written informed consent. Individual
institutional review boards of the University of Massachusetts
Medical School (#H-00009079) and other participating
enrollment sites approved the study.
Trained personnel abstracted clinical, demographic, labo-
ratory, and treatment characteristics of these participants
from the electronic health records. This included participants’
age, sex, race, education, income, insurance type, comorbidi-
ties (such as diabetes mellitus, hypertension, heart failure,
anemia, chronic kidney disease, and prior stroke), treatment
variables (ie, complete medication list), and laboratory values
including serum creatinine and hemoglobin (within the past
year). Using the relevant data, CHA2DS2-VASc and HAS-BLED
risk scores were calculated based on previously validated
methods.15 History of major bleeding, as defined by the
International Society on Thrombosis and Hemostasis crite-
ria,16 was also ascertained.
Geriatric Assessment
There were 6 components of the geriatric assessment
including frailty, cognitive function, social support, depressive
symptoms, vision, and hearing. Frailty was assessed using the
Cardiovascular Health Survey (CHS) frailty scale,17 a biological
model of frailty based on 5 components: unintentional weight
loss, exhaustion, low physical activity, slow gait speed, and
weakness as measured by grip strength. Scores on the CHS
Clinical Perspective
What Is New?
• In a diverse and contemporary cohort of older adults with
atrial fibrillation, over 20% of patients were treated with an
inappropriate direct-acting oral anticoagulant dose, with
most being underdosed. Drug-drug interactions were com-
mon.
• Prescription of inappropriate doses may be influenced by
clinician perception of higher bleeding risk or presence of
renal failure in addition to lack of familiarity with dosing
guidelines.
What Are the Clinical Implications?
• Clinicians should systematically assess for drug-drug inter-
actions, in addition to age, body weight, and renal function,
for prescription of accurate direct-acting oral anticoagulant
dose.
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frailty index range from 0 to 5 (higher scores=more frailty).
Participants with a score ≥3 were categorized as being frail.
Cognition was assessed using the Montreal Cognitive Assess-
ment (MoCA)test,18 with scores ranging from 0 to 30, with a
score of <23 used to indicate cognitive impairment.19 A
5-item modified version of the Social Support Scale and the
6-item Social Network scale was used to assess social
support.20 The Patient Health Questionnaire (PHQ-9) was
used to assess depressive symptoms.21 Patients self-reported
vision and hearing status based on standardized question-
naires evaluating symptoms of reduced vision such as
difficulty in reading the print on newspapers or doing work
or hobbies, difficulty in hearing during daily activities, or use
of hearing aids.22
Determining Appropriateness of DOAC Dose
We used the guidelines from FDA-approved package inserts6–9
and the 2018 European Heart Rhythm Association (EHRA)
practical guide on the use of non–vitamin K antagonist
anticoagulants23 for each drug with respect to absolute
contraindications (ie, creatinine clearance <15 mL/min and
not on dialysis, presence of a mechanical heart valve,
documented allergy to respective DOAC, active pathological
bleeding), age, renal function, and weight to create an algorithm
to evaluate the appropriateness of DOAC dosing. Creatinine
clearance was calculated for each patient from the serum
creatinine within 24 months of enrollment based on the
Cockcroft-Gault equation using ideal body weight.24
We created a comprehensive list of potentially interacting
drugs based on EHRA recommendations23 and the FDA-
reviewed package inserts6–9 for each DOAC. Briefly, all
participants who had an absolute contraindication were
deemed to be overdosed (Figure 1). If there were no absolute
contraindications, the algorithm evaluated dose appropriate-
ness based on age, renal function and body weight (for
apixaban), renal function alone (for rivaroxaban and edoxa-
ban), or renal function plus dronedarone use (for dabigatran).
If the participant was correctly dosed by these parameters, we
checked for drug-drug interactions. Participants in whom the
drug was contraindicated based on drug-drug interactions
were classified as either overdosed or underdosed based on
whether the drug interaction caused an increase or decrease
in serum levels of the DOAC. For example, ketoconazole
causes a rise in serum levels of all DOACs; hence, concomi-
tant use of ketoconazole and a DOAC was classified as an
overdose. On the other hand, for participants taking con-
comitant diltiazem, reduced strength dose was deemed to be
the “appropriate dose” if they also had a secondary indication
(age, renal function, or body weight) for dose reduction. For
the sake of uniformity, all yellow recommendations by the
EHRA guidelines (consider dose reduction or different DOAC if
≥2 “yellow” factors are present) were considered as a
requirement for dose reduction. Where there were discrep-
ancies between the EHRA recommendations and the DOAC
package insert, we used the EHRA recommendations as the
gold standard for determining dose appropriateness. The
exception to this rule was the EHRA recommendation to
consider dose reduction for concomitant use of antiplatelet
agents and HAS-BLED score >3, which were not included in
the algorithm.
Those SAGE-AF participants taking a DOAC who met all of
the above criteria were deemed to be on the guideline-
consistent DOAC dose for nonvalvular AF. Participants were
categorized as guideline-consistent, overdosed, or under-
dosed. These recommendations were drafted by the 2
pharmacists blinded to SAGE-AF data (P.C. and W.T.) and
were agreed upon by all authors. Two reviewers (S.R.S. and
C.W.) blinded to the DOAC dosing algorithm independently
reviewed all algorithm outputs (guideline-consistent, under-
dosing, or overdosing) to validate its findings. Manual chart
review findings were consistent with the output of the
algorithm described above in all cases.
Statistical Analysis
We compared participants on the guideline-directed dose of
DOACs versus off-label dose (either overdosed or under-
dosed) using chi-square test for categorical variables and
ANOVA for continuous variables. Because of the overall small
number of participants who were overdosed, we decided to
perform our subsequent analyses by grouping the underdosed
and overdosed into a single “off-label dose” category. We also
performed logistic regression analysis to estimate associa-
tions between geriatric elements (cognitive function, frailty,
social isolation, vision impairment, hearing impairment,
depression) and inappropriate dosing of DOACs. For these
analyses, we adjusted for characteristics that were significant
(P<0.05) in our univariate analyses in Table 1.
Results
Study Sample and Prevalence of Potentially
Inappropriate DOAC Dosing
The study sample is described in Figure 1. SAGE-AF recruited
a total of 1244 participants from 2016 to 2018, 1064 (86%) of
whom were prescribed oral anticoagulants for stroke preven-
tion. Of those prescribed anticoagulants, 466 (44%) were
prescribed a DOAC. We excluded 6 participants with missing
renal function. This yielded a total of 460 participants for the
present analysis. Of these, 235 (51%) were treated with
apixaban, 181 (39%) with rivaroxaban, 40 (9%) with dabiga-
tran, and 4 (1%) with edoxaban (Figure 2). The DOAC
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appropriateness algorithm evaluated each participants’ DOAC
dose in a stepwise manner (Figure 1). None of the partici-
pants had an absolute contraindication for DOAC therapy.
Once the age, renal function, and body weight criteria were
applied, 71 (15%) were found to be overdosed and 22 (5%)
were underdosed. After this, the drug-drug interactions were
factored in and 12 additional participants were found to be
overdosed and 1 additional participant was underdosed based
on the EHRA criteria. Overall, 355 patients (77%) were
receiving doses that were consistent with the package inserts,
82 (18%) were underdosed, and 23 (5%) were overdosed.
There were no significant differences in inappropriate dose
prescription among the different DOACs (P=0.308).
Baseline Characteristics
We compared the demographic, clinical, and geriatric char-
acteristics of participants who were prescribed guideline-
consistent dosing and those who were underdosed and
overdosed (Table S1). A higher proportion of participants who
were overdosed reported visual impairment (52% versus 29%,
P=0.04). Baseline characteristics of the cohort by dosing
group are presented in Table 1. Compared with participants
taking guideline-consistent doses of DOAC, those taking
potentially inappropriate doses were older (76.66.5 years
versus 73.86.3 years, P<0.001), had higher CHA2DS2-VASc
scores (4.71.9 versus 4.21.6, P=0.02), and were more
likely to have a history of major bleeding (27.6% versus 18.6%,
P=0.04) and renal failure (35.2% versus 20.9%, P=0.003). A
higher proportion of participants receiving potentially inap-
propriate doses were frail compared with those receiving the
guideline-consistent dose (21% versus 14%). However, this
difference did not achieve statistical significance in our
sample (P=0.07). There were no statistically significant
differences in rates of potentially inappropriate DOAC dosing
by sex, marital status, education, AF type, or study site
(Table 1).
DOAC Dosing by Drug and Renal Impairment
We performed additional analyses to clarify reasons for
inappropriate dosing and drug interactions. The rates of
guideline-consistent dose prescription were similar in partic-
ipants taking apixaban who met dose reduction criteria versus
those who appropriately received full-dose apixaban (83%
versus 79%). Among participants prescribed reduced-dose
≥ 2 of the 
following
VKA treated, 
n= 598 (56%)
SAGE-AF Cohort (n=1244)
AC, n=1064 (86%) No AC, n=180 (14%)
DOAC treated, n=466 (44%)
Included in analysis (n=460)
Missing renal 
funcon, n=6
Apply dose rules based on age, body 
weight, and renal funcon (n=460)
Inappropriate dose, n=93 (20%) Re-classified , n=12 (11%)
DR: CrCl 15-50 mL/min
CI: CrCl ≤ 15 mL/min or HD
DR: CrCl 30-50 mL/min +
dronedarone
CI: CrCl ≤ 15 mL/min or HD
Serum Cr ≥ 1.5 mg/dL
and/or
Age ≥ 80 years
and/or
Weight ≤ 60 kg
Apixaban
Apply drug-drug  
interacon rules
Inappropriate dose, n=105 (23%)
Appropriate dose, 
n=367 (80%)
Under-dosed, 
n=71 (15%)
Over-dosed, 
n=22 (5%)
Contraindicated, 
n=0 (0%)
Rivaroxaban
Edoxaban
Dabigatran
DR: CrCl 15-50 mL/min
CI: CrCl > 95 mL/min
Appropriate dose, 
n=355 (77%)
Under-dosed, 
n=82 (18%)
Over-dosed, 
n=23 (5%)
Contraindicated, 
n=0 (0%)
Figure 1. Breakdown of study sample of older adults with atrial fibrillation (SAGE-AF [Systematic Assessment of Geriatric Elements in Atrial
Fibrillation] cohort) treated with direct-acting oral anticoagulant (DOAC) medications as appropriate dose or inappropriate dose, ie, above
recommended dose (overdosed), below recommended dose (underdosed), or contraindicated. CrCl indicates creatinine clearance; DR, dose
reduction; VKA, vitamin K antagonist.
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rivaroxaban, 54% were taking the guideline-consistent dose
compared with 76% taking full-dose rivaroxaban (Table S2).
Drug-Drug Interactions
Overall, 115 (25%) of SAGE-AF participants taking DOACs
were coprescribed a medication with a potential DOAC-drug
interaction. A breakdown of the individual drugs that had
potential DOAC-drug interactions is shown in Table 2. Anti-
fungal agents, such as ketoconazole, that are absolutely
contraindicated with DOACs were used in 8 (2%) participants.
Calcium channel blockers, ie, diltiazem and verapamil, were
prescribed concomitantly with DOACs in 60 participants
(13%). Amiodarone was prescribed in 26 cases (6%).
Geriatric Elements and Potentially Inappropriate
DOAC Dosing
Although we observed that a greater proportion of SAGE-AF
participants receiving a potentially inappropriate DOAC dose
had visual impairment and were frail, in a logistic regression
model adjusted for age, history of renal failure, history of
major bleeding, and CHA2DS2-VASc score, none of the
geriatric elements—frailty, cognitive impairment, social isola-
tion, visual impairment, hearing impairment, or elevated
depressive symptoms—were associated with potentially
Table 1. Demographic and Clinical Characteristics of Older
Adults With AF Treated With DOACs in Relation to
Appropriateness of DOAC Dosing: SAGE-AF
Recommended
Dose of
DOAC (n=355)
Off-Label
Dose of
DOAC (n=105) P Value
Age, mean (SD), y 73.8 (6.3) 76.6 (6.5) <0.001*
Women 167 (47.0) 57 (54.3) 0.19
Non-Hispanic white 291 (82.0) 86 (81.9) 0.99
Married or living
as married
212 (59.7) 53 (50.5) 0.10
College graduate
or above
162 (45.6) 42 (40.0) 0.37
Insurance status
Commercial 45 (12.7) 10 (9.5) 
Medicare 260 (73.2) 85 (81.0) 0.12
Other 49 (13.8) 10 (9.5) 0.48
AF type
Paroxysmal 227 (63.9) 68 (64.8) 0.35
Persistent/long-standing,
persistent
93 (26.2) 23 (21.9) 0.10
Permanent 11 (3.1) 7 (6.7)
Frailty category
Nonfrail 133 (37.5) 39 (37.1) 
Prefrail 174 (49.0) 44 (41.9) 0.11
Frail 48 (13.5) 22 (21) 0.07
Cognitive impairment 136 (38.3) 49 (46.7) 0.13
Social isolation 53 (14.9) 16 (15.2) 0.94
Visual impairment 129 (36.3) 36 (34.3) 0.70
Hearing impairment 117 (33.0) 40 (38.1) 0.33
Depression 99 (27.9) 32 (30.5) 0.61
Anxiety 89 (25.1) 27 (25.7) 0.89
CHA2DS2-VASc
score, mean (SD)
4.2 (1.6) 4.7 (1.9) 0.02*
HAS-BLED score,
mean (SD)
2.8 (1.0) 2.9 (1.0) 0.40
Medical history
Heart failure 115 (32.4) 43 (41.0) 0.11
Peripheral
vascular disease
42 (11.8) 14 (13.3) 0.68
Hypertension 316 (89.0) 94 (89.5) 0.88
Diabetes mellitus 104 (29.3) 36 (34.3) 0.33
Major bleeding 66 (18.6) 29 (27.6) 0.04*
Gastrointestinal
bleeding
37 (10.4) 16 (15.2) 0.94
Stroke 29 (8.2) 11 (10.5) 0.46
Anemia 92 (25.9) 27 (25.7) 0.97
Continued
Table 1. Continued
Recommended
Dose of
DOAC (n=355)
Off-Label
Dose of
DOAC (n=105) P Value
Chronic lung
disease
99 (27.9) 24 (22.9) 0.31
Renal failure 74 (20.9) 37 (35.2) 0.003*
Fall in the
past 6 mo
68 (19.2) 22 (21.0) 0.68
Provider type
Cardiologist 113 (31.8) 26 (24.8) 0.44
Electrophysiologist 236 (66.5) 77 (73.3) 0.71
Internist 6 (1.7) 2 (1.9)
Site
Massachusetts 220 (62.0) 55 (52.4) 
Georgia 135 (38.0) 50 (47.6) 0.08
Aspirin use 82 (23.1) 19 (18.1) 0.28
Other antiplatelet
use
23 (6.5) 9 (8.6) 0.46
Continuous variables are presented as meanSD and categorical variables as number
(percentage). AF indicates atrial fibrillation; DOAC, direct-acting oral anticoagulant;
SAGE-AF, Systematic Assessment of Geriatric Elements in Atrial Fibrillation.
*P<0.05.
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inappropriate DOAC dosing (Table 3). However, advanced age
(odds ratio, 1.1; 95% CI, 1–1.1), history of renal failure (odds
ratio, 1.8; 95% CI, 1.1–3.0), and higher CHA2DS2-VASc score
(odds ratio, 1.1; 95% CI, 1.0–1.3) remained significantly
associated with potentially inappropriate dosing in the
adjusted model. We performed additional exploratory analy-
ses looking at associations between the geriatric elements
and underdosing only (Table S3), and results did not differ
substantively from results in the overall sample.
Discussion
To our knowledge, this is the first analysis examining
potentially inappropriate DOAC dosing in an older cohort of
235, 51%181, 39%
40, 9% 4, 1%
 Type of DOAC prescribed
Apixaban Rivaroxaban Dabigatran Edoxaban
356, 77%
82, 18%
22, 5%
 Frequency of potenally inappropriate dosing for the enre  cohort
Guideline-consistent dose Under-dosed Over-dosed
188 132 32
4
40
35
7
7 14 1
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
nabaxodEnartagibaDnabaxoraviRnabaxipA
Frequency of potenally inappropriate dosing by DOAC type
Guideline consistent dose Under-dosed Over-dosed
A
C
B
Figure 2. Frequency of direct-acting oral anticoagulant (DOAC) prescription by: (A) type of DOAC: apixaban, rivaroxaban, dabigatran, and
edoxaban; (B) frequency of guideline-consistent, underdosed, and overdosed prescription for the entire cohort; (C) frequency of potentially
inappropriate dosing by each DOAC type, among older patients with atrial fibrillation treated with DOAC in the SAGE-AF (Systematic Assessment
of Geriatric Elements in Atrial Fibrillation) study (n=460).
Table 2. Frequency of Drug-Drug Interactions by DOAC Prescribed in Older Patients With AF: SAGE-AF
Amiodarone Diltiazem Verapamil Dronedarone Erythromycin Ketoconazole Cyclosporine Tacrolimus Naproxen
Apixaban
n=235
10 (4) 28 (12) 5 (2) 4 (2) 1 (<1) 4 (2) 0 2 (2) 7 (3)
Rivaroxaban
n=181
12 (7) 21 (12) 3 (2) 1 (1) 0 4 (2) 0 0 4 (2)
Dabigatran
n=40
3 (8) 3 (8) 0 0 0 0 1 (3) 0 1 (3)
Edoxaban
n=4
1 (25) 0 0 0 0 0 0 0 0
Total
N=460
26 (6) 52 (11) 8 (2) 5 (1) 1 (<1) 8 (2) 1 (<1) 2 (<1) 12 (3)
Continuous variables are presented as meanSD and categorical variables as number (percentage). AF indicates atrial fibrillation; DOAC, direct-acting oral anticoagulant; SAGE-AF,
Systematic Assessment of Geriatric Elements in Atrial Fibrillation.
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participants with nonvalvular AF that includes an in-depth
phenotyping of both renal function and comprehensive
analysis of polypharmacy and drug-drug interactions. Our
results suggest that in our cohort of older patients with AF,
nearly a quarter were treated with potentially inappropriate
DOAC doses and the majority were underdosed. Older age,
history of renal failure, and higher stroke risk were associated
with significantly increased odds of receiving a potentially
inappropriate dose. Contraindications caused by drug-drug
interactions accounted for a significant proportion of the
potentially inappropriate prescribing. Contrary to our hypoth-
esis, our results suggest that age and stroke risk, but not the
presence of geriatric conditions, relates to potentially inap-
propriate prescribing.
Previous findings report wide ranges of inappropriate
dosing of DOACs. In ORBIT-AF II (Outcomes Registry for Better
Informed Treatment of Atrial Fibrillation II), 13% of participants
were found to be taking off-label doses.11 However, the
authors of this study did not report drug-drug interactions,
which accounted for a significant proportion of the inappro-
priate dosing observed in our study. A recent prospective
multicenter registry in Japan reported potentially inappropri-
ate dosing in 26% of all participants taking a DOAC, without
accounting for drug-drug interactions, suggesting that our
findings are valid but possibly underestimate the true rate of
inappropriate dosing.25 Perhaps the lower body weight of
Japanese participants with our US participants account for
some of the differences between cohorts, since body weight
factors into renal function calculation and constitutes one of
apixaban’s reduced dosing criteria. In contrast, a national
registry from Europe that included 530 participants with AF
observed a 32% prevalence rate of potentially inappropriate
DOAC dosing.26 However, this study used a strict application
of the EHRA guidelines. For example, the study mandated
dose reduction for concomitant use of antiplatelet agents
such as aspirin and higher bleeding risk, ie, HAS-BLED score
≥3, which are not reflected in the package insert6–9 or US
guidelines.27 We took a more pragmatic approach to deter-
mining whether drug-drug interactions existed and included
only those interactions backed by pharmacokinetic or clinical
data.
In our cohort, potentially inappropriate dosing was related
to older age, poor renal function, and higher CHA2DS2-VASc
score. Reasons for potentially inappropriate dosing may
include prescriber perception of higher bleeding risk in older
patients or those with renal failure. Interestingly, participants
with higher CHA2DS2-VASc score, ie, higher thromboembolic
risk, were more likely to be taking a potentially inappropriate
DOAC dose, even after adjusting for renal failure and major
bleeding. This may be driven by age. Since the majority of the
potentially inappropriate prescribing we identified was under-
dosing, our results suggest that older patients and those at
higher stroke risk may be at increased risk for receiving
subtherapeutic doses of DOACs. This finding is of great
clinical significance, particularly since DOAC dosing did not
relate to objectively measured frailty, a validated marker
associated with adverse reactions to cardiovascular medica-
tions.
We also looked at DOAC dose appropriateness by renal
function and body weight as recommended in the package
inserts and contemporary guidelines. Interestingly, there was
no difference in the rates of inappropriate dosing between the
full-dose and dose-reduced apixaban groups (21% versus
17%). Participants taking dose-reduced rivaroxaban were
more likely to be taking inappropriate doses than participants
taking full-dose rivaroxaban (46% versus 24%) (Table S4).
Perhaps this is because the dose reduction criteria for
apixaban (any 2 of 3 of the following: age ≥80 years, body
weight ≤60 kg, and serum creatinine ≥1.5 mg/dL) are easier
to apply correctly or because prescribers are using alternative
calculators to determine DOAC dosing. However, because of
the limited sample size in these analyses, these results should
be interpreted with caution and replicated in larger samples.
Previous studies have investigated the association of frailty
using a variety of frailty assessment scales with anticoagu-
lation prescription. One meta-analysis showed an association
between frailty and nonprescription of anticoagulants.28 There
have been no studies to our knowledge that investigated
potentially inappropriate DOAC dosing in relation to frailty. In
our cohort, components of a comprehensive geriatric assess-
ment, including frailty, were not related to inappropriate
Table 3. Demographic, Clinical, and Geriatric Elements in
Relation to Potentially Inappropriate Dosing of DOACs:
SAGE-AF
Geriatric Elements
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
Age 1.1 (1.0, 1.1) 1.1 (1.0, 1.1)*
History of renal failure 2.1 (1.3, 3.3) 1.8 (1.1, 3.0)*
History of major
bleeding
1.7 (1.0, 2.8) 1.5 (0.9, 2.5)
CHA2DS2-VASc score 1.2 (1.0, 1.3) 1.1 (1.0, 1.3)*
Frailty 1.6 (0.8, 2.9) 1.2 (0.6, 2.3)
Cognitive impairment 1.4 (0.9, 2.2) 1.1 (0.7, 1.8)
Social isolation 1.0 (0.6, 1.9) 1.0 (0.6, 1.9)
Visual impairment 0.9 (0.6, 1.4) 0.8 (0.5, 1.3)
Hearing impairment 1.3 (0.8, 2.0) 1.2 (0.7 1.9)
Elevated depressive
symptoms
1.1 (0.7, 1.8) 1.1 (0.7, 1.7)
DOAC indicates direct-acting oral anticoagulant; OR, odds ratio; SAGE-AF, Systematic
Assessment of Geriatric Elements in Atrial Fibrillation.
*P<0.05.
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dosing. These findings suggest that although prescribers
consider age in OAC prescribing, they may not consider
geriatric conditions in the context of DOAC dosing. Whether
these geriatric factors affect outcomes of OAC in participants
with AF still needs to be evaluated.
It is likely that the reasons behind prescription of
potentially inappropriate doses are multifactorial. First, DOAC
dosing recommendations can be complex and difficult to
recall—for example, apixaban dose reductions are recom-
mended based on serum creatinine, whereas dabigatran and
rivaroxaban are based on creatinine clearance. Most com-
mercial electronic health record systems report renal function
as glomerular filtration rate based on the Modification of Diet
in Renal Disease equation even though the pivotal trials with
DOACs used creatinine clearance as a measure of renal
function. There may be significant variations between the
two.29 Previous studies have shown higher stroke risk with
underdosing and elevated bleeding risk with inappropriate
overdosing of DOACs; hence, adherence to guideline-directed
dosing is important nonetheless.11–13,25 Second, drug-drug
interactions are numerous and can be cumbersome to apply,
leading to variations in dosing. Perhaps, inclusion of drug
interaction calculators in electronic health records would
improve dose prescribing in such scenarios. Third, prescrip-
tion of such doses may be intentional—clinicians may be
looking at trends in renal function as opposed to a single point
check, as we did, and thus may reduce doses based on higher
perceived bleeding or fall risk or may choose to forgo
recommended dose reduction in patients with a high throm-
boembolic risk profile. This is not something we could
determine from our data but should be explored in future
studies.
Study Strengths and Limitations
We leveraged data from a contemporary, comprehensive,
diverse cohort of older patients with AF who had a high
degree of comorbidity, and performed in-depth phenotyping of
drug dosing and interactions, clinical comorbidities, and frailty
status. We developed an algorithm for DOAC dose appropri-
ateness that can potentially be used with other data sets and
electronic health record–based quality assessment tools to
improve DOAC dosing and validated all cases with blinded
chart review. However, there are certain limitations of this
study. These data cannot elucidate reasons for potentially
inappropriate dosing, or whether this inappropriate dosing
was intentional and part of informed clinical decision-making
or represents an error. Since outcome data are still being
collected, we cannot examine whether potentially inappropri-
ate dosing is associated with increased risk of thromboem-
bolic or bleeding outcomes as it has been in other cohorts.
We will explore these associations as our follow-up data
become available. In addition, we collected participants’ renal
function at the time of entry into the study. It is possible that
prescribing physicians had access to multiple data points and
based their dosing on trends in renal function. We checked for
drug interactions for those drugs listed in the 2018 EHRA
recommendations and package inserts. However, we
acknowledge that the list of drugs metabolized by the P-
glycoprotein transporter and CYP3A4 enzyme is extensive and
their individual effects on each of the 4 DOACs are not yet
completely understood. We did not include antiplatelet agents
in our drug-drug interactions algorithm since concomitant use
is justified according to some guidelines29 and there is no
consensus on dose reduction for this interaction. The modest
number of participants receiving certain DOACs and inappro-
priate dosing of these DOACs limited our statistical power to
detect associations. Last, our algorithm needs to be indepen-
dently validated in other cohorts to establish its utility for
clinical use.
Conclusions
In this contemporary and well-characterized cohort of older
adults with AF receiving DOACs we observed that nearly one
quarter were prescribed a potentially inappropriate dose, with
most being underdosed. Systematic assessment of drug-drug
interactions is important for prescription of accurate DOAC
dosing. Inappropriate dosing was more likely among older
patients with higher CHA2DS2-VASc scores and presence of
renal dysfunction but was not associated with frailty or other
geriatric conditions. Further research is needed to determine
the association between dosing and clinical outcomes and
strategies to prevent unintentional inappropriate dosing by
prescribers.
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Table S1. Demographic and Clinical Characteristics of older adults with atrial fibrillation 
treated with DOACs in relation to appropriateness of DOAC dosing: SAGE-AF. 
Characteristic (Total n=460) Guideline consistent 
dose (n=355) 
Over-dosed 
(n=23) 
Under-dosed 
(n=82) 
p-value 
Age 73.8 (6.3) 76.1 (7.0) 76.8 (6.4) 0.67 
Female 167 (47.0) 12 (52.2) 45 (54.9) 0.82 
Non- Hispanic White 291 (82.0) 20 (87.0) 66 (80.5) 0.48 
Married or living as married 212 (59.7) 9 (39.1) 44 (53.7) 0.18 
College graduate or higher 162 (45.6) 11 (47.8) 31 (37.8) 0.46 
Insurance status 
   Commercial 
   Medicare 
   Other 
 
45 (12.7) 
260 (73.2) 
49 (13.8) 
 
4 (17.4) 
16 (69.6) 
3 (13.4) 
 
6 (7.3) 
69 (84.2) 
7 (8.5) 
 
 
0.13 
0.91 
AF Type 
   Paroxysmal 
   Persistent/Long standing persistent 
   Permanent 
 
227 (63.9) 
93 (26.2) 
11 (3.1) 
 
14 (60.9) 
7 (30.4) 
1 (4.4) 
 
54 (65.9) 
16 (19.5) 
6 (7.3) 
 
0.95 
0.30 
CHA2DS2VASC score (M, SD) 4.2 (1.6) 4.6 (1.6) 4.7 (2.0) 0.75 
HAS-BLED score (M, SD) 2.8 (1.0) 3.0 (1.0) 2.8 (0.9) 0.45 
Medical History      
D
ow
nloaded from
 http://ahajournals.org by on April 8, 2020
   Anemia 
   Chronic lung disease 
   Diabetes 
   Fall in the last 6 months 
   GI bleeding 
   Heart failure 
   Hypertension 
   Major bleeding 
   Peripheral vascular disease  
   Renal failure 
   Stroke 
92 (25.9) 
99 (27.9) 
104 (29.3) 
68 (19.2) 
37 (10.4) 
115 (32.4) 
316 (89.0) 
66 (18.6) 
42 (11.8) 
74 (20.9) 
29 (8.2) 
7 (30.4) 
6 (26.1) 
8 (34.8) 
6 (26.1) 
3 (13.0) 
8 (34.8) 
20 (87.0) 
5 (21.7) 
3 (13.0) 
9 (39.1) 
2 (8.7) 
20 (24.4) 
18 (22.0) 
28 (34.2) 
16 (19.5) 
13 (15.9) 
35 (42.7) 
74 (90.2) 
24 (29.3) 
11 (13.4) 
28 (34.2) 
9 (11.0) 
0.56 
0.68 
0.95 
0.50 
0.81 
0.50 
0.65 
0.48 
0.96 
0.66 
0.75 
Provider Type 
   Cardiologist 
   Electrophysiologist 
   Internist 
 
113 (31.8) 
236 (66.5) 
6 (1.7) 
 
8 (34.8) 
14 (60.9) 
1 (4.4) 
 
18 (22.0) 
63 (76.8) 
1 (1.2) 
 
0.94 
0.17 
 
Aspirin use 82 (23.1) 6 (26.1) 13 (15.9) 0.26 
Other anti-platelet use 23 (6.5) 1 (4.4) 8 (9.8) 0.43 
Frailty category 
   Non-frail 
 
133 (37.5) 
 
9 (39.1) 
 
30 (36.6) 
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   Pre-frail 
   Frail 
174 (49.0) 
48 (13.5) 
8 (34.8) 
6 (26.1) 
36 (43.9) 
16 (19.5) 
0.41 
0.50 
Cognitive Impairment 136 (38.3) 11 (47.8) 38 (46.3) 0.90 
Social isolation 53 (14.9) 2 (8.7) 14 (17.1) 0.33 
Visual impairment 129 (36.3) 12 (52.2) 24 (29.3) 0.04 
Hearing impairment 117 (33.0) 11 (47.8) 29 (35.4) 0.28 
Depression 99 (27.9) 9 (39.1) 23 (28.1) 0.31 
Anxiety 89 (25.1) 7 (30.4) 20 (24.4) 0.56 
 
Continuous variables are presented as mean ± standard deviation and categorical variables are 
presented as n (%). 
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Table S2. Frequency of full dose and reduced dose DOAC prescription in relation to dose 
appropriateness: SAGE-AF. 
 Guideline dose Guideline consistent Under-dose Over-dose 
Apixaban  187 (80) 40 (17) 8 (3) 
Full Dose 5mg bid 177 (79) 39 (18) 7 (3) 
Reduced dose 2.5 mg bid 10 (83)  1 (8) 1 (8) 
Rivaroxaban  132 (73) 35 (19) 14 (8) 
Full dose 20mg daily 119 (76) 33 (21) 5 (3) 
Reduced dose 15mg daily 13 (54) 2 (8) 9 (38) 
Dabigatran  32 (80) 7 (18) 1 (3) 
Full dose  150 mg bid 32 (80) 7 (18) 1 (3) 
Reduced dose* 75 mg bid - - - 
Edoxaban  4 (100) 0 0 
Full dose 60 mg daily 4 (100) 0 0 
Reduced dose* 30 mg daily - - - 
 
*None of the participants were prescribed Dabigatran 75mg bid or Edoxaban 30mg daily.  
Continuous variables are presented as mean ± standard deviation and categorical variables are 
presented as n (%). 
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Table S3. Demographic, Clinical, and Geriatric Elements in Relation to under-dosing of 
DOACs: SAGE-AF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Continuous variables are presented as mean ± standard deviation and categorical variables are 
presented as n (%). 
 
 
 
 
Geriatric Elements Under-dosed, N (%) OR (95% CI) 
Age 76.8 (6.4) 1.1 (1.0, 1.1) 
Prior renal failure 28 (34.2) 1.9 (1.2, 3.3) 
Prior major bleeding 24 (29.3) 1.8 (1.1, 3.1) 
CHA2DS2VASC score 4.7 (2.0) 1.2 (1.0, 1.4) 
Frailty 16 (19.5) 1.5 (0.7, 2.9) 
Cognitive Impairment 38 (46.3) 1.4 (0.9, 2.3) 
Social Isolation 14 (17.1) 1.2 (0.6, 2.2) 
Visual impairment 24 (29.3) 0.7 (0.4, 1.2) 
Hearing impairment 29 (35.4) 1.1 (0.7, 1.8) 
Depression 23 (28.1) 1 (0.6, 1.7) 
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Table S4. Age, body weight and renal function in relation to DOAC dose appropriateness: 
SAGE-AF. 
 Guideline dose Total  Guideline 
consistent dose 
Under-
dose 
Over-dose 
Apixaban (Total)  235  187 (80) 40 (17) 8 (3) 
Less than 2/3: 
• Age>=80 
• Wt <=60kg 
• S Cr >=1.5mg/dl 
5mg bid 223 177 (79) 39 (18) 7 (3) 
>=2 of: 
• Age>=80 
• Wt <=60kg 
• S Cr >=1.5mg/dl 
2.5 mg bid 12 10 (83)  1 (8) 1 (8) 
Rivaroxaban 
(Total) 
 181 132 (73) 35 (19) 14 (8) 
Cr Cl >= 50 ml/min 20mg daily 157 119 (76) 33 (21) 5 (3) 
Cr Cl 15 -50 ml/min 15mg daily 24 13 (54) 2 (8) 9 (38) 
Cr Cl <15 ml/min or 
HD 
Contraindicated 0    
Dabigatran (Total)  40 32 (80) 7 (18) 1 (3) 
Cr Cl >=50 ml/min 150 mg bid 34 28 (82) 5 (15) 1 (3) 
Cr Cl 30-50ml/min 
and not receiving 
dronedarone 
150mg bid 6 4 (67) 2 (33) 0 
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Cr Cl 30-50ml/min 
and receiving 
dronedarone 
75 mg bid 0 - - - 
CrCl<15 ml/min or 
HD 
Contraindicated 0 - - - 
Edoxaban (Total)  4 4 (100)   
CrCl 50-95ml/min 60 mg daily 4 4 (100)   
CrCl 15- 50 ml/min 30 mg daily 0 - - - 
CrCl >95 ml/min Contraindicated 0 - - - 
 
Continuous variables are presented as mean ± standard deviation and categorical variables are 
presented as n (%). 
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